Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b

Zhongjie Hu*, Ying Liu, Lixia Qiu, Zuopeng Fan, Wei Nie, Shan Liang and Ronghua Jin

Abstract

Background: Substitutions of amino acid (aa) 70 in the core region of hepatitis C virus genotype 1b (HCV 1b) are a predictor of the non-virological response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy. The aim of our study was to develop quantitative real-time reverse transcription polymerase chain reaction (qPCR) assays to quantify wild-type (70 W) and mutant (70 M) strains of HCV 1b.

Methods: We used the TaqMan system to quantify strains 70 W and 70 M. Codon 70 in the HCV 1b core region can be either CGN or CAN, therefore degenerate TaqMan minor groove binder (MGB) probes with inosine were used. We determined detection limits, sensitivity and specificity of the methods developed. Direct sequencing and cloning of the HCV core region were used to confirm the reliability of our new system. Serum samples from 138 Chinese patients infected with HCV 1b were examined with the system we developed and compared with results obtained from the Roche TaqMan RT-PCR HCV RNA quantitation system.

Results: Degenerate MGB probes were able to clearly distinguish 70 W from 70 M. The detection limit was 10^3 copies/mL. Cross-reactivity tests confirmed the specificity of our method. Our system can effectively quantify 70 W and 70 M for 99.6% of patients with HCV 1b. Further tests involving cloning and sequencing confirmed the reliability of our system.

Conclusions: We developed an assay system using degenerate TaqMan MGB probes with inosine to quantify wild-type and mutant viral RNAs of the HCV 1b core region at aa 70. Our developed assay system had high levels of sensitivity and accuracy, and could prove useful in investigating dynamic changes during PEG-IFN/RBV therapy to assess virological responses.

Keywords: Hepatitis C virus, Genotype 1b, Amino acid 70 substitutions, Degenerate probes, Inosine, Quantitative PCR

Background

Hepatitis C virus (HCV) infection represents a major public health problem as it is a major cause of chronic hepatitis. Considerable numbers of HCV patients develop liver cirrhosis and hepatocellular carcinoma (HCC). Over the last 20 years, several antiviral drugs have been developed to treat chronic hepatitis C, including pegylated interferon (PEG-IFNα), ribavirin (RBV) and direct-acting antivirals (DAAs). Until 2011, the combination of PEG-IFNα and RBV (PEG-IFNα/RBV) was the approved treatment for chronic hepatitis C [1]. New therapeutic strategies with DAAs aim towards higher efficacy, pan-genotypic activity, shortened treatment duration, easier administration and improved tolerability and patient adherence [2].

IFN-sparing and -free regimens with or without ribavirin will enter clinical practice in the next few years. However, in some developing countries, such as China, or in some rural and poor regions, use of PEG-IFNα/RBV still represents a standard treatment approach and is sometimes the only available therapy. The long-term response to this therapy remains unsatisfactory, especially in patients infected with HCV genotype 1b (HCV 1b). Additionally, PEG-IFNα/RBV combination therapy is accompanied by adverse events. Prediction of the response to antiviral treatment before initiation or in the early phase of therapy would be advantageous. Several
factors have been associated with responses to PEG-IFN/RBV therapy; some are associated with the host, such as interleukin 28B single nucleotide polymorphisms (IL28B SNPs), gender, race, age, and obesity [3-7], while some are virus-associated, such as viral genotype, viral load, amino acid (aa) substitution in the core and non-structural (NS) 5A region [8-10].

Substitution at aa 70 of the core protein is one of the most important factors, along with IL28B polymorphisms [11-15]. For patients with the IL28B rs8099917 genotype, 12% of those with Gln70 (His70) had a sustained viral response (SVR), while 50% of patients with Arg70 were conferred an SVR [16]. Detection of aa 70 substitutions is important to predict an early non-virological response (NVR) and is also the basis to study the mechanisms of IFN treatment resistance. To investigate wild-type (Arg70; 70 W) and mutant (Gln/His70; 70 M) strains of HCV 1b, several methods are available including direct sequencing, mutation-specific polymerase chain reaction (PCR) assays [17] and quantitative PCR assays [18]. However, the sensitivity and specificity of these tests are limited. These methods are insufficient for quantifying viral RNAs and cannot be used to investigate the dynamic response of 70 W and 70 M to antiviral therapy.

We attempted to develop an absolute quantitation system for 70 W and 70 M using degenerate TaqMan minor groove binder (MGB) probes with inosine. We also sought to determine the sensitivity, specificity, and reproducibility of our improved system and correlate our results with those from direct sequencing and cloning sequencing.

Results
Specificity of probes and optimization of qPCR assays
Probes could detect plasmid templates with one-base mismatch; however, reaction efficiency was lower than that when well-matched plasmids were used. When 5 × 10^7 copies of the wild-type plasmids (CGG of codon 70) were tested using the mutant probe (CAI), which had a base mismatch, approximately 30 cycles were required before the crossing threshold was reached (Figure 1A). This compares with 15 cycles for the matching probe (CGI). When fewer than 5 × 10^2 copies of the wild-type plasmid were tested using the mutant probe, no signal was detected by 45 cycles. All serial dilutions of the templates could be detected by the matched probe by 41 cycles. When 5 × 10^7 copies of the mutant plasmid (CAG of codon 70) template were used in conjunction with the wild-type probe (CGI), approximately 34 cycles were required before the crossing threshold was reached, while only 17 cycles were required for the matching probe (CAI). When fewer than 5 × 10^3 copies of the mutant plasmid were tested with the wild-type probe, no signal was detected by cycle 45. All serially diluted templates could be detected by the matching probe in 42 cycles (Figure 1B). The slope of the curve for Rn vs. cycles for the mismatched reaction was lower than that of the well-matched reaction.

To eliminate the impact of non-specific amplifications, when qPCR assays were prepared, a cross-reaction control with 5 × 10^7 copies of a one-base mismatch plasmid was used. When data were analyzed, a manual baseline was used to cover the curve vertex of the cross-reaction control to ensure specificity of the system.

Sensitivity and detection limits of the probes
The wild-type and mutant plasmids were mixed at ratios of 99:1, 90:10, 80:20, 50:50, 20:80, 10:90, and 1:99, corresponding to final concentrations of 10^7–10^1 copies/μL. Using the plasmid mixture as a template, qPCRs were performed. In all cases, wild-type probes could successfully

![Figure 1](http://www.virologyj.com/content/11/1/148)
detect 1% of wild-type plasmids in the 100 copies/μL mixture, or 10% for the 10 copies/μL mixture (Table 1). Similarly, 1% of the mutants among the 100 copies/μL mix, or 10% of the 10 copies/μL mixture, were successfully detected with the mutant probes. The calculated relative ratios agreed with those of the template plasmids (Figure 2).

**Quantitation of aa 70 substitutions in clinical samples**

HCV 70 W and 70 M in serum samples from 138 Chinese patients with HCV 1b were successfully quantified. Sequences from the HCV core region were confirmed by direct sequencing. Using relative ratios, we identified three categories to compare by direct sequencing: less than 1% (wild-type); 1–99% (mixed); and greater than 99% (mutants; Table 2). We found a mix of genotypes in 94% (129/138) of samples. Approximately 68% (88/129) of cases could be detected only by our novel system. The mutant strain was dominant (>50%) in 23% (32/138) of patients.

**Accuracy of our novel system**

When the system with normal TaqMan MGB probes was used, 89.1% (123/138) of the sums of wild-type and mutant viral loads were comparable with results from the Roche diagnostic system (Table 3). In 15 cases, the results were less than 20% of those from the Roche system. When our improved system with degenerate probes was used, only a single patient’s result was not comparable with those from the Roche diagnostic system.

**Table 1 Detection limits when using the plasmid mixture as templates**

| Probes W:M plasmid ratio | W 10⁴ | M 10⁵ | W 10⁶ | M 10⁷ |
|--------------------------|-------|-------|-------|-------|
| 99:1                     | D     | D     | D     | D     |
| 90:10                    | D     | D     | D     | D     |
| 80:20                    | D     | D     | D     | D     |
| Wild-type                | D     | D     | D     | D     |
| 50:50                    | D     | D     | D     | D     |
| 20:80                    | D     | D     | U     | D     |
| 10:90                    | D     | D     | D     | D     |
| 1:99                     | D     | U     | D     | D     |
| 99:1                     | U     | D     | D     | D     |
| 90:10                    | U     | D     | D     | D     |
| 80:20                    | U     | D     | D     | D     |
| Mutant                   | D     | D     | D     | D     |
| 50:50                    | D     | D     | D     | D     |
| 20:80                    | D     | D     | D     | D     |
| 10:90                    | D     | D     | D     | D     |
| 1:99                     | D     | D     | D     | D     |

W/M, ratio of wild-type to mutant plasmids.

D, detectable.

U, undetectable.

Direct sequencing of the core region showed that 83.3% (115/138) of patients’ core genes completely matched primers used in our novel system. We also found that the core genes in 23 patients contained one or two mismatched sites with the primers. However, only one mismatched site (G162A) was near the 3’ end of the sense primer. For the other 22 cases, the mismatched sites were near the 5’ ends of the sense (A154G, C159T) or antisense (A297G/T, C300T, G302A) primers and exerted very little influence on the PCR results. For 89.9% (124/138) of cases, the major codon 70 types were CGG or CAG; for the other 14 cases, they were CGA, CGT, CAA, CAT, or CAC.

**Table 2 Prevalence of aa 70 substitutions in 138 Chinese patients with HCV 1b who had not been treated**

| Core 70 mutant (%) | Direct sequencing |
|--------------------|-------------------|
| Wild-type          | Mixed             | Mutant |
| <1                 | 5                 | 0      | 0     |
| 1-10               | 43                | 0      | 0     |
| 10-15              | 13                | 1      | 0     |
| 15-20              | 2                 | 6      | 0     |
| 20-30              | 1                 | 12     | 0     |
| 30-40              | 1                 | 14     | 0     |
| 40-50              | 0                 | 8      | 0     |
| 50-80              | 0                 | 0      | 0     |
| 80-90              | 0                 | 0      | 1     |
| 90-99              | 0                 | 0      | 27    |
| >99                | 0                 | 0      | 4     |

Direct sequencing of the core region showed that 83.3% (115/138) of patients’ core genes completely matched primers used in our novel system. We also found that the core genes in 23 patients contained one or two mismatched sites with the primers. However, only one mismatched site (G162A) was near the 3’ end of the sense primer. For the other 22 cases, the mismatched sites were near the 5’ ends of the sense (A154G, C159T) or antisense (A297G/T, C300T, G302A) primers and exerted very little influence on the PCR results. For 89.9% (124/138) of cases, the major codon 70 types were CGG or CAG; for the other 14 cases, they were CGA, CGT, CAA, CAT, or CAC.

Accuracy of ratios for wild-type to mutant viral loads

The 14 cases with codon 70 types other than CGG and CAG were selected for TA cloning and sequencing. Our results showed that the ratios of wild-type to mutants as determined by our novel system were comparable with those from the cloning and sequencing experiments. For patients with codon 70 types other than CGG and CAG,
systems with degenerate probes containing inosine can fix the errors caused by normal probes (Table 4).

**Discussion**

The study presented here is based on reports that substitution of arginine by glutamine at aa 70 in the HCV 1b core region is an independent and significant marker associated with an NVR to PEG-IFN/RBV therapy. A significant association between HCV core substitutions and treatment outcome has been reported in several studies [8,19]. However, other studies have described that only a variation at residue 70 is associated with treatment response. The aa 70 substitution has been identified as the most important factor for PEG-IFN/RBV treatments with the exception of IL28B polymorphisms [3,12,13,16].

Direct sequencing is the most accurate method for determining aa 70 substitutions, but sensitivity is limited for samples with mixed genotypes. A minor genotype present at levels of about 15–20% might not be detected by direct sequencing. Direct sequencing is not able to quantify virus RNAs and cannot be used to investigate the dynamic response to antiviral therapy of wild-type and mutant strains. Because the sequencing method is costly, Okamoto et al. [17] developed a new method, the amplification refractory mutation system (ARMS) reverse transcription PCR (RT-PCR), and this became widely adopted. In the HCV 1b core region, several codons encode arginine (CGG/C/U/A) in wild-type proteins; however, the second base is always a “G”. Similarly, the second base of the codon encoding glutamine or histidine (CAG/C/U/A) in mutant proteins is always an “A”. Thus, detection of wild-types or mutants based on a single-base difference can be achieved by designing the common second base (A or G) at the 3’ end of primers. Compared with direct sequencing, the mutation-specific PCR is simpler, quicker, and more convenient with a satisfactory detection rate, frequency of competitive-type cases, and re-examination rate. However, the authors also pointed out that the system excludes the presence of a minor type. Detailed examination, such as sequence analysis using cloning, might be necessary when a competitive type is indicated by the detection system. Moreover, the system is unable to quantify virus RNAs. To quantify the aa 70 mutations, Nakamoto et al. [18] developed a real-time ARMS RT-PCR assay. Mutation-specific primers are able to distinguish the difference between wild-type and mutant plasmids at the same quantitative levels. The real-time ARMS RT-PCR is more convenient because it uses a fluorescent signal instead of restriction enzyme digestion, gel electrophoresis, or sequence analysis.

**Table 3 Ratio of HCV RNA loads as determined by novel systems with degenerate probes or normal MGB probes compared with those determined by Roche Diagnostic Systems**

| Ratio of HCV RNA loads | Tested with normal probes (%) | Tested with degenerate probes (%) |
|------------------------|-------------------------------|----------------------------------|
| <2                     | 94 (68.1)                     | 121 (87.7)                      |
| 2–5                    | 29 (210)                      | 16 (11.6)                       |
| >5                     | 15 (10.9)                     | 1 (0.7)                         |

**Table 4 Correlation of results from the novel system with degenerate probes, normal probes, the Roche diagnostic system, and from sequencing**

| No. | Roche system | Normal probes | Degenerate probes | Cloning sequencing | Matched with normal probes | Matched with degenerate probes |
|-----|--------------|---------------|-------------------|--------------------|---------------------------|-------------------------------|
|     | RNA Load$^2$| Ratio$^2$ Wild-type (%) | Ratio$^2$ Wild-type (%) | Codon 70 | 4CGG/1CAG/14CGA/1 N.D.$^3$ | 1CGG/1CAG | 18CGN/1CAN |
| 1   | 7.2          | 0.19          | 82.1              | 1.33               | 98.5                      | 4CGG/1CAG | 14CGA/1 N.D.$^3$ | 18CGN/1CAN |
| 2   | 6.3          | 0.01          | 0.0               | 1.27               | 2.6                       | 13CAA/7CAT | None | 20CAN |
| 3   | 7.0          | 0.08          | 4.2               | 1.38               | 92.0                      | 2CAG/18CGA | 2CAG | 2CAN/18CGN |
| 4   | 6.6          | 0.07          | 100.0             | 0.71               | 97.5                      | 15CGA/5 N.D. | None | 15CGN |
| 5   | 6.6          | 0.08          | 100.0             | 0.87               | 100.0                     | 1CGG/19GT | 1CGG | 20CGN |
| 6   | 5.6          | 0.17          | 4.8               | 1.39               | 2.7                       | 3CAG/17CAA | 3CAG | 20CAN |
| 7   | 6.5          | 0.02          | 63.2              | 0.70               | 92.7                      | 2CAA/16CGA/2 N.D. | None | 2CAN/16CGN |
| 8   | 7.9          | 0.04          | 0.0               | 0.80               | 0.0                       | 18CAA/2 N.D. | None | 18CAN |
| 9   | 7.1          | 0.03          | 2.0               | 1.48               | 1.5                       | 19CAC/1 N.D. | None | 19CAN |
| 10  | 6.4          | 0.13          | 20.6              | 1.47               | 4.2                       | 1CGG/3CAG/16CAA | 1CGG/3CAG | 1CGN/19CAN |
| 11  | 5.6          | 0.12          | 95.6              | 1.18               | 96.4                      | 3CAG/17CGA | 3CAG | 20CGN |
| 12  | 7.4          | 0.08          | 96.0              | 1.32               | 8.0                       | 1CGG/15CAT/4 N.D. | 1CGG | 1CGN/15CAN |
| 13  | 6.7          | 0.08          | 91.3              | 0.96               | 9.8                       | 2CGG/16CAA/2 N.D. | 2CGG | 2CGN/16CAN |
| 14  | 6.3          | 0.18          | 95.5              | 1.90               | 97.5                      | 4CGG/16CGA | 4CGG | 20CGN |

$^2$RNA loads (Log$_{10}$ copies/mL) as determined by the Roche Diagnostic System.

$^3$Ratio of RNA loads (copies/mL) as determined by our novel system to those determined by the Roche Diagnostic System.

$^3$No data available.
of PCR products. Importantly, the system can quantify the proportion of core substitutions. The specificity of the system is dependent upon the mutation-specific primers; a minor genotype might be masked when the ratio is less than 1:100. Furthermore, with the SYBR Green method, primer dimers and non-specific amplification artifacts can decrease specificity.

To overcome these disadvantages, we developed a TaqMan two-step RT-PCR system with high sensitivity and specificity using MGB probes to quantify the main genotypes of aa 70. Our system cannot be used for aa 70 genotypes other than CGG/CAG, which account for about 13% of patients with HCV 1b.

Considering the variability of HCV RNA, primers and probes should be designed to match HCV quasispecies as much as possible. We first determined a consensus sequence of the HCV 1b core gene based on 489 sequences [20]. Primers were then designed based on conserved regions. Our results showed that for 115 of 138 patients, the primers matched well with the HCV core gene. Of the 23 patients with mismatched bases at the primer sites, 22 were near the 5’ end of the primers and had little influence on the PCR results. A single mismatched site (G162A) was near the 3’ end of the sense primer and resulted in reduced PCR efficiency. Because primer mismatches are critical to the success of qPCR assays, primer sequences must be modified if mismatches are frequent. The frequencies of possible primer mismatches, including G162A, were very low, especially for sites near the 3’ end, and possibly lowered PCR efficiency (Table 5). Therefore, the primers designed for the system will work well for the vast majority of patients.

For the probes, because the target site was codon 70, the only way to improve specificity is to shorten the length of the probe. The MGB probe was the best option because when it is hybridized to a complementary target, the MGB molecule folds into duplex and hyper-stabilizes, allowing the use of shorter, more specific probe sequences [21]. Although MGB probes can detect single-base mutations, the system we developed can still detect part of plasmid templates with one-base mismatch. The reason for this might be because there were too many G and C bases around codon 70, therefore the G/C to A/T ratio in probes was too high (>80%). Reaction efficiency and crossing threshold were lower than those in corresponding plasmids. The slope of the curve for Rn vs. cycles for the mismatched reactions was much lower than those for the well-matched reactions. When the cross-reaction control with $5 \times 10^7$ copies of one-base mismatch plasmid was used, a manual baseline could be moved to cover the curve vertex of the cross-reaction control. The curves for the standards were at the exponential growth stage, with parallelism between curves still very good.

When compared with the Roche diagnostic system, which is widely used in clinics, our novel system exhibited good comparative performance. When the system with normal TaqMan MGB probes was used, the results for 15 patients were less than 5-fold from those of the Roche diagnostic system. For one case, it was because there was a mismatched site near the 3’ end of the sense primer. For the other 14 cases, different codon 70 types (CGA, CGT, CAA, CAT, and CAC) were identified by direct sequencing. The normal probes designed for “CGG or CAG” were not strong matches for the sequences. When our improved system with degenerate probes was used, all results were comparable with those from the Roche diagnostic system. The degenerate probes were designed with inosine as the third base of codon 70. Inosine can indiscriminately pair with adenine, thymine, guanine or cytosine. This allows for a probe design that spans SNPs without the polymorphism disrupting the annealing efficiency of probes. To determine the proportion of patients who were suitable for probes, the types of codon 70 for the 489 independent HCV 1b gene sequences were analyzed. Of the codon 70 types, 87.1% are CGG and CAG, and can be effectively tested by the system with normal TaqMan MGB probes. CGN and CAN account for 99.6% of codon 70 types and

### Table 5 Frequencies of possible primer mismatches based on 489 sequences of the HCV 1b core gene

| Sense primer | Anti-sense primer | Frequency of mismatch (%) |
|--------------|-------------------|--------------------------|
| nt 5’       | nt 5’             |                          |
| 148 A       | 302 C             | 0.00                     |
| 149 G       | 301 G             | 0.20                     |
| 150 G       | 300 G             | 0.41                     |
| 151 A       | 299 G             | 0.61                     |
| 152 A       | 298 G             | 0.20                     |
| 153 G       | 297 T             | 0.20                     |
| 154 A       | 296 G             | 0.61                     |
| 155 C       | 295 A             | 0.20                     |
| 156 T       | 294 C             | 0.20                     |
| 157 T       | 293 A             | 0.20                     |
| 158 C       | 292 G             | 0.20                     |
| 159 C       | 291 A             | 0.20                     |
| 160 G       | 290 C             | 0.20                     |
| 161 A       | 289 G             | 0.20                     |
| 162 G       | 288 C             | 0.20                     |
| 163 C       | 287 C             | 0.20                     |
| 164 G       | 286 A             | 0.20                     |
| 165 G       | 285 T             | 0.20                     |
| 166 T       | 284 C             | 0.20                     |
| 167 C       | 283 A             | 0.20                     |
| 168 T       | 282 C             | 0.20                     |
| 169 T       | 281 C             | 0.20                     |
| 170 T       | 280 C             | 0.20                     |
can be detected with our improved system using degenerate probes (Table 6).
The detection limit of our assay (1.0 × 10^3 copies/mL) was not satisfactory. To detect 1% of mutation, samples with viral loads greater than 1.0 × 10^5 copies/mL would be required. However, it is very difficult to further improve sensitivity in the laboratory. Therefore, the novel detection system is mainly for patients with viral loads greater than 1.0 × 10^5 IU/mL at baseline. In many published studies, the inclusion criteria involve viral loads greater than 100 kIU/mL [8,13,19]. Among the 138 patients tested in the study, only the viral loads of five patients were lower than 1.0 × 10^5 copies/mL. Our novel assay is useful for the majority of patients. We are now focusing on a larger study, and our novel quantitative detection system is expected to be useful for investigating the dynamic response of wild-types and mutants to PEG-IFNα/RBV therapy, and the effects of R70Q/H substitutions on resistance to PEG-IFNα/RBV therapy.

Conclusions
We developed a detection system for quantitatively determining aa 70 substitutions in the HCV 1b core region. Our novel developed system had good sensitivity and accuracy, and was helpful in quantifying wild-type and mutant viral RNAs. It also provides a way to investigate the dynamic responses of wild-type and mutant viral RNAs to PEG-IFNα/RBV therapy.

Methods
Ethics statement
Our study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by The Ethical Committee of Beijing Youan Hospital, Capital Medical University. Written informed consent was obtained from each patient participating in this study.

Table 6 Proportions of codon 70 types among 489 independent HCV 1b gene sequences

| Codon 70 types in the HCV 1b core region | Frequency | %  |
|-----------------------------------------|-----------|----|
| CGG                                     | 246       | 50.3|
| CAG                                     | 180       | 36.8|
| CGA                                     | 26        | 5.3 |
| CAA                                     | 18        | 3.7 |
| CAT                                     | 12        | 2.5 |
| CGT                                     | 3         | 0.6 |
| CAC                                     | 2         | 0.4 |
| CGG                                     | 1         | 0.2 |
| CTT                                     | 1         | 0.2 |
| Total                                   | 489       | 100 |

Serum samples
Between January 2012 and April 2014, serum samples were obtained from 138 Chinese patients with chronic HCV 1b infection that had not been treated. Patients were from the Department of Hepatology, Beijing Youan Hospital, Capital Medical University and were used to develop and evaluate our novel detection system. Total viral loads were determined by TaqMan qPCR (AmpliCor, Roche Diagnostic Systems, Shanghai, China). Samples were kept at −80°C until required.

HCV RNA extraction and reverse transcription
We extracted HCV RNA from serum samples (140 μL) using a QIAamp Viral RNA Mini Kit according to the manufacturer’s protocol (Qiagen, Shanghai, China). We prepared cDNA by reverse transcription with random hexamers and TaqMan Reverse Transcription Reagents (Applied Biosystems). Reverse transcription reaction conditions involved incubation at 25°C for 10 min, then 42°C for 40 min, and finally 95°C for 5 min.

Plasmid DNA controls
The HCV core gene was amplified from the serum of a patient with HCV 1b using PCR and specific primers (5′-AAAT GCC TGG AGA TTT GGG-3′ and 5′-TTG GAG CAG TCG TTC GTG-3′). Thermal cycling conditions involved denaturation at 95°C for 10 min, followed by 40 cycles of amplification (30 s at 95°C, 30 s at 55°C, and 1 min at 72°C) and a 7-min extension step at 72°C after the 40th cycle. Amplicons were purified using a QIAquick PCR Purification Kit (Qiagen) after agarose gel electrophoresis, and then cloned into pCR-TOPO2.1 (Invitrogen) according to the manufacturer's protocol. Positive clones were picked and codon 70 types were identified by sequencing (Beijing AuGCT DNA-SYN Biotechnology Co., Ltd). The codon 70 wild-type was CGG. We then made a plasmid carrying a mutant codon 70 (CAG). Site-directed mutagenesis was performed using a QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s protocol and specific complementary primers (5′-CAAGGCCTGGAGA TTG GCC CGG CGA GGG CAG GCC CTG CTG-3′ and 5′-CAG GCC CTG CCC TCG GCC CGG CGA GCC TTG-3′). The introduction of the mutation was confirmed by sequencing. Plasmids containing wild-type or mutant codon 70 were serially diluted 10-fold to provide a dilution range of 10^7–10^0 copies/μL.

HCV 1b core region consensus sequence and codon 70 types
We downloaded 1336 HCV 1b gene sequences, including the full-length core region, from the European HCV database (euHCVdb), HCV Databases from Los Alamos National Laboratory, HCV Database (HCVdb) from the
Table 7 Primers and TaqMan MGB probes used for detection of aa 70 substitutions

| Type            | Primer name | Binding position (nt) | Sequence (5’–3’)                      |
|-----------------|-------------|-----------------------|---------------------------------------|
| Primers         | sense       | 148–167               | AGG AAG ACT TCC GAG CGG TC             |
|                 | antisense   | 302–286               | CGG GGT GAC AGC AGC CA                 |
| Degenerate probes | 70 W(CGN)   | 203–217               | FAM-CTC GCC GIC CGG AGG-MGB            |
|                 | 70 M(CAN)   | 203–219               | VIC-CTC GCC AIC CGG AGG-GC-MGB         |
| Normal probes   | 70 W(CGG)   | 204–217               | FAM-TGG CGG GCC CGA GG-MGB             |
|                 | 70 M(CAG)   | 203–218               | VIC-CTC GCC AGC CGG AGG G-MGB          |

CR, core region; nt, nucleotides; I, inosine.

Viral Bioinformatics Resource Center (VBRC), and National Center for Biotechnology Information (NCBI) [20]. Of these, 847 sequences were excluded (814 were from repeated cases at different time points, 19 from cultured cells, eight from plasmids, and six from animal experiments). The remaining 489 sequences were used to determine the consensus sequence of the HCV 1b core region and codon 70 types with the GENETYX software application (Genetyx Corp., Tokyo, Japan).

Primer and TaqMan probe design for qPCR assays
Primers were synthesized by Sangon Biotech (Shanghai) Co. Ltd. Compared with the TaqMan MGB probes for the main types of codon 70 (CGG and CAG), inosine was used to design two degenerate TaqMan MGB probes for 70 W (CGN) and 70 M (CAN) (Table 7). Probes were purchased from Invitrogen (Shanghai). We performed qPCR assays in a final volume of 50 μL; each reaction contained 5 μL of cDNA, 0.3 μM each primer, 0.1 μM probe and 25 μL of 2x LightCycler® 480 Probes Master Mix (Roche Applied Science, Shanghai, China). Two separate reactions were prepared to detect the wild-types and mutants, but were simultaneously carried out on the same thermal cycling system. Thermal cycling conditions involved an initial denaturation step at 95°C for 10 min, followed by 45 cycles of amplification (15 s at 95°C and 1 min at 60°C). All assays were performed in triplicate on a LightCycler® 480 real-time PCR System (Roche Applied Science) and results were analyzed using LightCycler® 480 Software (Roche Applied Science).

Nucleotide sequencing of the HCV core gene
We used direct sequencing to determine the HCV core gene sequence from the sera of 138 patients. Nucleic acids were amplified by PCR using specific primers (5’-ATG GCC TGG AGA TTT GGG-3’ and 5’-TTG GAG CAG TCG TGC GTG-3’). All samples were initially denatured at 95°C for 10 min and then subjected to 40 cycles of amplification (30 s at 95°C, 30 s at 55°C, and 1 min at 72°C), with an additional 7 min final extension step at 72°C. Amplicons were purified with a QIAquick PCR Purification Kit (Qiagen) after agarose gel electrophoresis and then used for direct sequencing (Beijing AuGCT DNA-SYN Biotechnology Co. Ltd).

The ratio of 70 W to 70 M was determined by cloning and sequencing for some of the patients and results compared with those for the improved system to evaluate accuracy. Cloning was carried out using TOPO TA Cloning Kits (Invitrogen) according to the manufacturer’s protocol. We conducted PCRs using 5’-TGG TGG AAG GCG ACA ACC-3’ and 5’-GCC GAC GAG CGG AAT GT-3’ as sense and antisense primers, respectively. We then randomly picked 20 colonies for each sample and had them sequenced (Beijing AuGCT DNA-SYN Biotechnology Co. Ltd).

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Conceived and designed the experiments: HZJ JRH. Performed the experiments: LY QLX FZP NW LS. Analyzed the data: HZJ JRH. Contributed reagents/materials/analysis tools: LY QLX. Wrote the paper: HZJ JRH. All authors read and approved the final manuscript.

Acknowledgements
The study was supported by Beijing outstanding talents training funds, China (No. 2010DD03034000009); foundation-clinical research cooperation projects from Capital Medical University, China (No. 1000172053-11L61); Youan liver diseases & AIDS funds, China (No. BJYAH-2011-073); and special project of capital clinical characteristic application research, China (No. Z121107001012086). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Received: 15 May 2014 Accepted: 12 August 2014
Published: 15 August 2014

References
1. Ohtsuji S, Fukushima W, Tanaka T, Habi D, Tamori A, Sakaguchi H, Takeda T, Kawada N, Seki S, Nishiguchi S, Shiomi S, Hirota Y: Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case–control study. Hepatol Res 2006, 36:201–208.
2. Manns MP, von Hahn T: Novel therapies for hepatitis C – one pill fits all? Nat Rev Drug Discov 2013, 12:595–610.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Munt AJ, Sukkowksi M, Mchutchison JS, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:390–401.
4. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuuria K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Haas Y, Nishiguchi S, Kole A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugachia F, Inumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to
pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.  
Nat Genet 2009, 41:105–1109.
5. Suppiah V, Moldovan M, Athenstiel G, Berg T, Weltman M, Abate MS, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smeddle A, Fagomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100–1104.
6. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529–535.
7. Gao B, Hong F, Rodava S: Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004, 39:880–890.
8. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48:373–380.
9. Pascu M, Martus P, Höhne M, Wiedemann B, Hofp U, Schreier E, Berg T: Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NSS-NS3D: a meta-analysis focused on geographical differences. Gut 2004, 53:1345–1351.
10. Shiokawa H, Matsumoto A, Joshi S, Komatsu M, Tanaka N, Unemura T, Ichijo T, Yoshizawa K, Kyosawa K, Tanaka E, Nagano interferon Treatment Research Group: Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48:1753–1760.
11. Hashimoto Y, Ochi H, Abe H, Hayashida Y, Tsuge M, Mitsu F, Hiraga N, Imamura M, Takahashi M, Nelson Hayes C, Ohishi W, Kudo M, Tsunoda T, Kamataki N, Nakamura Y, Chayama K: Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2011, 83(6):981–988.
12. Aletski E, Arnlind B, Elard M, Lagging M, Nilsson S, Norkrans G, Wahlberg T, Weijstål R, Westin J, Lindh M: Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011, 11:24.
13. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamataki N, Nakamura Y, Chayama K: HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011, 60(2):261–267.
14. Fukushima T, Taketomi A, Motomura T, Okano S, Nimiyama A, Abe T, Uchimura H, Soejima Y, Shirabe K, Matsuura Y, Meehar A: Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139(5):1577–1585.
15. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H: Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology 2012, 55(6):417–425.
16. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H: Amino acid substitution in hepatitis C virus core region and genetic variation near the interferon 28b gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52(2):421–429.
17. Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsu Y, Tazawa H: A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. J Virol Methods 2007, 141(1):1–5.
18. Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujikawa K, Fuku K, Kanai F, Imazeki F, Yokosuka O: Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 2009, 44(7):872–877.
19. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007, 79:1686–1695.
20. Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N: Characteristic mutations in Hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci 2009, 100(12):2465–2468.
21. Afonina IA, Reed MW, Lustby E, Shishkinia KS, Belousov YS: Minor groove binder-conjugated DNA probes for quantitative DNA detection by hybridization-triggered fluorescence. Biotechniques 2002, 32(4):940–944, 946–949.